

Investor News

Markus Georgi
Senior Vice President
Investor Relations & Sustainability

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
F +49 6172 608-2488
markus.georgi@fresenius.com
www.fresenius.com

March 30, 2020

Fresenius postpones 2020 Annual General Meeting

- **New date will be specified and communicated as soon as reliable planning is possible**
- **Health and safety of shareholders and employees is our priority**

Due to the coronavirus pandemic, Fresenius SE & Co. KGaA postpones its Annual General Meeting scheduled for 20 May 2020 to a later date within the current financial year. As one of the consequences, this will lead to a postponement of the resolutions regarding the appropriation of net income 2019 and the payout of the dividend. The Company will set and communicate a new date as soon as the conditions for reliable planning and safe execution of the Annual General Meeting are once again in place.

“At present, the primary task is to slow down the spread of the coronavirus and thus to contain it as far as possible. With this decision, we are also supporting this common goal. The health and safety of our shareholders and employees have highest priority,” said Stephan Sturm, CEO of Fresenius.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2019, Group sales were €35.4 billion. On December 31, 2019, the Fresenius Group had 294,134 employees worldwide.

For more information visit the Company’s website at www.fresenius.com.
Follow us on Twitter: www.twitter.com/fresenius_ir.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms,

results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz,
Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick